

Claim 37, line 2, delete "about" and insert
therefor --greater than--.

REMARKS

Claims 6, 13 and 22-38 presently appear in this case. Claim 32 has been allowed if amended to appear in independent form. Claims 6, 13, 22-31 and 33-38 have been rejected. The official action of March 9, 2000, has now been carefully studied. Reconsideration and allowance are hereby respectfully urged.

Briefly, the present invention relates to a method for treating a neoplastic condition sensitive to interferon by administering interferon via oromucosal contact in an amount which is greater than a dose of the same interferon which induces a pathological response when parenterally administered. That dose is preferably greater than 20×10^6 IU of interferon for a 60 kg human. The invention also relates to a composition for oromucosal contact in the form of a lozenge or buccal tablet which has greater than 20×10^6 IU of interferon and a vehicle or excipient which facilitates contact with the mucosa lining the mouth or throat upon administration.

Claim 33 has been rejected under 35 U.S.C. §112, second paragraph, as being indefinite. The examiner states